Global Institute Of Stem Cell Therapy And Research
US: +1-800-914-7836

What's new

Latest news

Groundbreaking Treatment for Severe COVID-19 using Stem Cells

GROUNDBREAKING TREATMENT FOR SEVERE COVID-19 USING STEM CELLS

The corona virus has affected our lives ever since its emergence in late 2019 which was later declared a pandemic in 2020. Every day there is some news of death/affliction from COVID – 19 in almost every part of this planet. With a lot of research focused on developing a vaccine has resulted in a few effective ones already in production in some countries including India, and are actively being used for mass immunization. However, the vaccines are of not much importance to those already suffering from the disease.

Therefore, as needed research is also taking place for developing an effective therapeutic regimen for treating the disease. In an effort in the last few months umbilical cord blood stem cells are being used for treating severe cases of COVID-19 in clinical trials.

The University of Miami Miller School of Medicine researchers led a unique ground breaking randomized controlled trial showing umbilical cord derived from mesenchymal stem cell infusions to safely reduce the risk of death and in hastening the time to recovery for the severest COVID-19 patients.

COVID-19 induces severe inflammation in the afflicted individuals. Because of their powerful anti-inflammatory and healing properties stem cells, immaterial of the source of origin either from umbilical cord blood or the placenta or any other source, are being applied for treating patients infected with COVID-19.

The recovery from COVID – 19 after stem cell treatment

null

During the month of March, 2020, umbilical cord stem cells were intravenously administered to seven COVID-19 patients. Symptoms of all patients significantly alleviated within two days of the treatment, and no side effects were recorded. Three of these patients were discharged within 10 days after stem cell treatment. Onward the study has been expanded to treat more than thirty patients, and the results showed significant improvement in their conditions after receiving the therapy.

The rationale of using mesenchymal stem cells for treating COVID – 19

Mesenchymal stem cells, the most often used type of stem cells, are also multipotent adult stem cells present in most human tissues including the umbilical cord. These cells can self-renew while dividing, and can differentiate into multiple types of tissues leading to a robust clinical research agenda in stem cell therapy.

It has been demonstrated that mesenchymal stem cells reduce the acute lung injury and inhibit the cell-mediated inflammatory responses induced by SARS-CoV-2. Furthermore, because these cells lack the angiotensin-converting enzyme 2 (ACE2) receptor that SARS-CoV-2 uses for viral entry into cells, mesenchymal stem cells are resistant to infection.

Study of data on the use of stem cells in COVID-19

Data demonstrate that stem cells are safe and well tolerated in patients. Also, the stem cell treated patients had meaningful improvements in lung function, got off the ventilators faster than those not treated with stem cells. Stem cell treated patients experienced improved rate of survival as well.

The next step would be to study the effectiveness of stem cells in COVID-19 patients who become ill enough close to be intubated in order to determine if stem cell infusions could prevent the disease progression.
It is very likely that hyper-immune and hyper-inflammatory responses in autoimmune diseases might hold clue rooted reasons unknown about why some COVID-19 patients develop severe form of the disease while others do not.

In the month of May, 2020, the US Food and Drug Administration (FDA) also approved a phase 1/2a trial for assessing the use of umbilical cord mesenchymal stem cells for treating severe COVID-19 patients.

A Novel protein could reverse muscle wasting during aging or trauma or even during severe disease-specific conditions

A NOVEL PROTEIN COULD REVERSE MUSCLE WASTING DURING AGING OR TRAUMA OR EVEN DURING SEVERE DISEASE-SPECIFIC CONDITIONS

Researchers at the Australian Regenerative Medicine Institute – Monash University in Melbourne were successful in discovering a factor that triggers the muscle stem cells to regenerate that can help in regeneration of muscle, and also in the return of normal movement even after severe muscle trauma.

It is a well-known fact that muscle stem cells are the engines that drive the tissue’s growth and they have the capability of repairing the muscles due to any injury. For instance, people with severe muscle wasting diseases such as muscular dystrophy and war veterans who survive catastrophic limb injuries regain their muscle strength with the help of these muscle stem cells.

However, as we age we lose much of our muscle strength as our stem cells do not seem to work as well due to the aging factor. Therefore, growing these cells in the lab and then using them therapeutically to replace damaged muscles is quite difficult if not impossible.

Research on factors that trigger muscle stem cells-

Researchers have now discovered a factor that triggers these muscle stem cells to proliferate and help heal. Through a mouse model of severe muscle damage, injections of this naturally occurring protein have led to the complete regeneration of the muscle and the return of the normal movement after severe muscle trauma.

The scientists/researchers have indeed studied the regeneration of skeletal muscle in zebrafish that has become one of the best animal models for studying stem cell regeneration, as fish are quicker in reproducing, easier to manipulate experimentally and these fish share 70% of its genes with humans. Due to their transparent body, it results in scientists visualize the actual regeneration of living muscle.

The scientists noticed that the cells that migrated to a muscle injury in these fish and were successful in identifying a group of immune cells called the macrophages that have a role in triggering the muscle stem cells to regenerate.

The Role of Macrophages in cuddling the muscle stem cells-

The scientists observed that the macrophages cuddle the muscle stem cells, which then started to divide and proliferate. The starting of this process resulted in the macrophages move on and cuddling the next muscle stem cell that helped in healing the wound.

Macrophages are the cells that flock to sites of any infection or injury in the body, which helps in removing the debris, and promote healing. Two types the macrophages exist in the body – one those move to the injury site rapidly and remove the debris, while the other ones come in slower and stick around doing the long-term cleanup.

The Importance of NAMPT – An Overview

The research team found eight genetically different types of macrophages in the injury site and out of that one type, in particular, was the cuddler. This affectionate macrophage releases a substance called nicotinamide phosphoribosyltransferase (NAMPT). By removing these macrophages from the zebra fish and adding the NAMPT to the aquarium water, the scientists found that they could stimulate the muscle stem cells to grow and heal thereby effectively replacing the need for the macrophages.

Recent experimentation of placing a hydrogel patch containing NAMPT into a mouse model of severe muscle wasting has led to the significant replacement of the damaged muscle. Now, discussions are on to take NAMPT to clinical trials for use of this compound in the treatment of muscle disease and injury.

What are 6 health problems that might be treated by stem cells?

WHAT ARE 6 HEALTH PROBLEMS THAT MIGHT BE TREATED BY STEM CELLS?

Stem cells are compleletly or partially undifferentiated or unprogrammed cells which are capable of developing into numerous types of cells and serving different functions in different parts of the body. The majority of cells in the human body are differentiated cells which means that they can serve only a specific purpose in a particular organ such as red blood cells that can only carry oxygen or carbon dioxide with the blood.

Stem cells can divide and make an indefinite number of copies of themselves. Stem cells can either remain stem cells or turn into differentiated cells such as red blood cells or muscle cells.

How stem cell could be useful for treating different diseases.

Scientists involved in stem cell research believe that stem cells can be useful for understanding mechanisms of diseases and treating those. Stem cells are being used to:

  • Replace damaged cells of organs or tissues,
  • Resore functions of tissues or organs that do not work properly,
  • Investigate mechanisms of genetic defect caused diseases,
  • Research how diseases develop or why certain cells become cancerous,
  • Test safety and effectiveness of new drugs.

The stem cell field has grown rapidly over the last two decades with stem cell treatments that include technologies to treat or prevent a disease condition. Stem cells have the potential to help treat numerous diseases by generating healthy new cells of almost all tissues.

Stem cell therapy for treating hematopoietic and genetic disorders

Stem cell therapy is being used to treat hematopoietic and genetic disorders. For instance in a cord blood transplant, stem cells are infused into a patient’s blood stream after which they help in healing and repairing of damaged tissues. Upon successful engraftment of the stem cells, the patient’s blood and immune systems are regenerated.

Six Health Problems that might be treated with stem cell therapy-

There are a wide range of diseases that are treatable with stem cells derived from cord blood or from other sources like bone marrow and peripheral blood. The diseases treatable by stem cells include acute and chronic forms of leukemia, myeloproliferative disorders, and many more.

The following six health problems might successfully be treated by stem cell therapy also known as regenerative medicine-

  • Leukaemia

Doctors are replacing cells damaged by chemotherapy or leukemia by performing stem cell transplant. Stem cell therapy is also serving as a way for supporting the patient’s immune system to fight some types of cancer and blood related diseases.

  • Diabetes – type 1

Embryonic stem cells when transplanted into people with type 1 diabetes is showing some very encouraging results towards the management of this disease.

  • Stroke

Stem cells are being used in clinical trials with evidence that when combined with clot busting or mechanical thrombectomy therapy enhances recovery. Stem cells injected into distant arteries or veins travel to the site of stroke in the brain fueling the repairing and recovery processes.

  • Kidney failure

Mesenchymal stem cells when administered independently are known to aid in kidney repair in cases of kidney failures.

  • Liver cirrhosis

The mechanism of mesenchymal stem cells or MSCs for treating liver cirrhosis /diseases has been evaluated from various perspectives. Adult stem cell therapies help induce the rapid production of hepatocytes in patients with liver cirrhosis.

  • Ulcerative colitis

Mesenchymal stem cells have displayed their immense potential for suppression of overactive immune response and for healing inflamed tissues. Therefore, these are emerging as a promising treatment of ulcerative colitis and inflammatory bowel disease or IBD, the diseases suspected to be rooted in localized inflammation in digestive tract.

The stem cell therapy has great potentials for treating and/or managing the six diseases mentioned above.

GIOSTAR honored by Insight Magazine as the “Company of the Month”

fa96881b-25e1-4d31-a04f-d1336ace8a26
GIOSTAR got the distinction of being named in the Insightscare.com Magazine as the “Company of the Month”. The Insightscare.com Magazine, which is one of the leading online healthcare magazines, published the journey of GIOSTAR becoming the world renowned institute of stem cell research and therapy.

The magazine also covered the interview given by Dr. Anand Srivastava – Chairman & Co-Founder of GIOSTAR for his expert opinion and future developments in the field of stem cell research and therapeutics.

The January-2021 edition of Insightscare.com also mentioned the able leadership of Mr. Deven Patel – CEO, President and Co-Founder of GIOSTAR who was honored with the USA Congressional Recognition for his efforts in spreading the advancement of stem cell science around the globe.

The magazine covered Dr. Anand Srivastava’s profound success and expertise in the field of stem cell biology, protein biochemistry, molecular biology, immunology, gene therapy and clinical research.

The magazine mentioned the big news of GIOSTAR FDA approval under compassionate use program and treatment of 53-year old critical COVID patient having recovered significantly after being infused with Stem Cells (MSCs).

Insightscares.com also reported how under the leadership of Mr. Deven Patel – GIOSTAR is heading the development of stem cell transplant program for four different state governments in India covering a population of approx. 155 million. The report further states that GIOSTAR in collaboration with the Gujarat government is building the world’s largest state-of-the-art stem cell treatment hospital in India.

The magazine also spelled out how GIOSTAR’s team members have been involved in the development and utilization of stem cell based clinical protocols related to malignant and non-malignant diseases for over two decades. Overall, GIOSTAR is named as a company that is poised to become the largest institute of excellence in the field of stem cell research and therapy on the earth.

GIOSTAR: Leading India towards an Immune Future – Insightscare

Leading India towards an Immune Future

In August 2020, a 53-year-old COVID patient who was in a comatose state, struggling to hold on to life, was infused with Mesenchymal stem-cells taken from an umbilical cord. The results of this infusion were nothing less than enthralling as the patient recovered significantly in over three weeks.

This medical marvel was made possible by Global Institute of Stem Cell Therapy and Research (GIOSTAR), which is on a mission to administer the safest and most effective stem cell therapies and to deliver the highest quality care through its hospitals.

GIOSTAR was founded on the vision to provide stem cell-based therapy to people suffering from all kinds of degenerative or genetic diseases around the world. The company is evidently a leader in developing cutting edge stem cell-based technology, supported by leading scientists with pioneering publications in the area of stem cell biology. GIOSTAR was also one of the first company/research institute in the world which received USA-FDA approval in April 2020 to treat COVID-19 patients with stem cells.

The company’s primary focus is on discovering and developing a cure for human diseases through state-of-the-art and unique stem cell-based therapies and products. The company’s intellectual property, intellectual assets and technology have been developed over its team working on research projects funded to the tune of more than several hundred million dollars.

GIOSTAR is a coalition of esteemed and illustrious scientific minds in the field of genetic and stem cell science. The company’s team members have been involved in the development and utilization of stem cell based clinical protocols related to malignant and non-malignant diseases for the last 20 years.

The company’s leaders are associated with leading universities and research institutes of USA. GIOSTAR is affiliated with University of California San Diego Medical College (UCSD), University of California Irvine Medical College (UCI), Salk Research Institute, San Diego, Burnham Institute for Medical Research, San Diego, University of California Los Angeles Medical College (UCLA), USA, Harvard Medical School, Imperial College, London.

“Our team has developed several research collaborations and has an extensive research experience in the stem cell therapy which is documented by several publications in revered scientific journals,” says Dr Anand Srivastava, the Chairman and Co-founder of GIOSTAR.

Dr Srivastava’s profound success has its root in his unique background and expertise in stem cell biology, protein biochemistry, molecular biology, immunology, in utero transplantation of stem cell, tissue targeting, gene therapy and clinical research.

There are many scientists who can work in a narrowly defined field, but few have broad and multidisciplinary experience to carry out clinical research in a field as challenging as stem cell biology, cancer, and gene therapy. Dr Srivastava’s wide-spectrum expertise is rare in clinical research and perfectly crafted to fit ideally with the GIOSTAR’s projects for stem cell transplant, cancer, and gene therapy research. Dr Srivastava is also serving as stem cell director for the government of Gujarat, India and is in the process of establishing the stem cell program for Gujarat, Government of India.

The team at GIOSTAR is reaching heights of success also under the able leadership of Mr. Deven Patel, the CEOPresident and Cofounder. Mr. Patel was honoured with USA Congressional Recognition for his efforts in spreading the advancement of stem cell science around the world. He was also bestowed with the Asian Heritage Award for his business leadership in the field of stem cell science.

GIOSTAR, under the leadership of Mr. Patel, is heading the development of stem cell transplant program for four different State Governments in India with total population of approx. 155 million. The company, in collaborations with Government of Gujarat, India, has founded the world’s largest state-of-the-art stem cell treatment hospital in India. GIOSTAR is also in process of developing additional facilities in China, Thailand, Colombia, Bahamas, Dubai, and Australia.

Talking about how GIOSTAR successfully found the solution to treat COVID-19 related health issues, Dr Srivastava explains, “COVID-19 infection leads to uncontrolled release of proinflammatory cytokines known as ‘cytokine storms’ that potentially lead to fatal damage of many organs of the body. MSCs have specific characteristics that, when infused in the bloodstream, neutralize proinflammatory cytokines (through ‘immunomodulation’), down-regulate the inflammatory gene actions and send messages to regenerate damaged lung and other tissues, which may help in managing COVID-19.” GIOSTAR is also gearing up to start its clinical trial for patients with aftereffects of COVID-19 on lungs and other organs.

We asked Dr Srivastava about his opinion on the necessity for businesses to align their offerings with newer technological developments, especially when it comes to changing industry trends and customer preferences, to which he replied, “Scientific research is an ever-evolving process. GIOSTAR being hard core research organization allows it to be at the forefront of new innovations and possible cure for several incurable disease. This same mindset has made us one of the first research institutes in the world to get very early approval form USA-FDA to treat COVID-19 patients with stem cells.”

Mr. Patel on the other hand shared a few tokens of knowledge through the commercial perspective of regenerative medicine development, he says, “The pharma and scientific research businesses are very competitive, at very high level of science and at very high cost. Therefore, a simple advice to aspiring entrepreneurs is to first get their ducks in the row and get your finances figured out way in advance, otherwise it is very easy to bankrupt the company in this volatile economy.”

GIOSTAR’s plan to continue scaling its operation, keeping in mind the unpredictable future, can be viewed to be agile and ready to run. Pertaining to stable finances, the company’s pipeline of several technologies is very robust and in line with its projections. GIOSTAR is poised to be the largest stem cell research and therapy company on the earth. The company is already becoming a synonym for the stem cell treatment.

Read More : https://insightscare.com/giostar-leading-india-towards-an-immune-future/

Civic Youth Conclave is a two-day virtual deliberation to be held on 9th and 10th January 2021

WhatsApp Image 2021-01-06 at 10.28.10 AM

Civic Youth Conclave is a two-day virtual deliberation to be held on 9th and 10th January 2021. It is modeled on United Nations Conference with participants from all across the world. The Secretariat has envisioned this conference to be a platform to provide exposure to students and a safe space for them to put forth their cogent opinions. We are striving to make a difference and empower the youth for they are the future generation. We believe that MUN can lead to a deeper understanding of real-world problems and hence, lead to the youth finding solutions towards absolute world peace.

 

Make An Inquiry

We are here to help you

WordPress Video Lightbox